Shanghai Haohai Biological Technology (HKG:6826, SHA:688366) recorded a 7% decline in attributable profit in the first quarter to 90.3 million yuan from 97.5 million yuan in the year-ago period, a Friday Hong Kong bourse filing said.
Earnings per share were 0.39 yuan in the quarter, down from 0.42 yuan in the corresponding period of the last fiscal year.
The ophthalmic products manufacturer's revenue fell 4.3% to 618.5 million yuan in the three months from 646 million yuan a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.